InvestorsHub Logo
Followers 58
Posts 10316
Boards Moderated 1
Alias Born 09/21/2016

Re: MayoMobile post# 300673

Friday, 02/26/2021 7:55:39 AM

Friday, February 26, 2021 7:55:39 AM

Post# of 469812
MayoMobile...clearly an "Above and Beyond effort" here. Just exceptional. MY GUESS is the MJF people must be delighted w/AVXL and A2-73 deliverables. They have here, the real truth about PDD. EXCELLENT STUFF.

- PDD is a tough indication, three failures recently across the industry. PDD has multiple pathologies which makes it so hard to treat. Our data is intriguing because we had a strong signal across the patients. All domains will be readout in the upcoming data release. Dose-dependent improvement in PDD, 30mg stopped decline, 50 mg improved patient. The 50mg patients "came out of the study with less dementia". 70% of this data has direct correlation with ADAS-COG (AD primary endpoint). REM was also improved and so was digital vigilance and episodic memory. No safety issues.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News